P/E ratio for KYORIN Pharmaceutical (4569.T)
P/E ratio as of April 2024 (TTM): 21.1
According to KYORIN Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.0595. At the end of 2022 the company had a P/E ratio of 16.9.
P/E ratio history for KYORIN Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 16.9 | -34.3% |
| 2021 | 25.7 | 45.4% |
| 2020 | 17.7 | -1.46% |
| 2019 | 18.0 | -39.42% |
| 2018 | 29.7 | 66.09% |
| 2017 | 17.9 | -27.15% |
| 2016 | 24.5 | 74.09% |
| 2015 | 14.1 | 3.81% |
| 2014 | 13.6 | 0.16% |
| 2013 | 13.5 | 21.83% |
| 2012 | 11.1 | 16.56% |
| 2011 | 9.54 | -20.58% |
| 2010 | 12.0 | 2.79% |
| 2009 | 11.7 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.